



## **Exelixis Announces June 12 Webcast of Presentation at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference**

June 11, 2007

SOUTH SAN FRANCISCO, Calif., June 11 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George Scangos, president and chief executive officer of Exelixis will present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference at 3:20 p.m. (PT) / 6:20 p.m. (ET) on Tuesday, June 12, 2007.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at <http://www.exelixis.com>.

### About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

SOURCE Exelixis, Inc.

CONTACT: Investor, Charles Butler, Director, Investor Relations, +1-650-837-7277, [cbutler@exelixis.com](mailto:cbutler@exelixis.com), or media, Soleil Maxwell Harrison, Senior Manager, Corporate Communications, +1-650-837-7012, [sharrison@exelixis.com](mailto:sharrison@exelixis.com), both of Exelixis, Inc.

Web site: <http://www.exelixis.com>